Unlocking the Mystery of LATE Dementia: A Neurologist's Perspective
Dementia is a growing concern, and a new player has entered the scene. Memory specialists at MUSC Health are shedding light on a lesser-known form of dementia called LATE, which stands for Limbic-predominant Age-related TDP-43 Encephalopathy. This condition, affecting over 10% of people aged 65 and above, and a third of those aged 85+, has only recently been recognized, and it's a game-changer.
But diagnosing LATE is no simple task. Here's the catch: Neurologist Dr. Nicholas Milano explains, "We don't have specific tests for LATE. It's a diagnosis of exclusion." Unlike Alzheimer's, there's no biomarker blood test or brain scan to confirm its presence.
So, what's the latest on LATE?
- Diagnostic Guidelines: Experts have developed criteria to help doctors identify LATE, focusing on memory-related symptoms and the progression of the disease.
- Potential Treatments: Researchers are exploring treatments, with one clinical trial already underway. The goal is to find ways to manage LATE, even though its symptoms resemble Alzheimer's.
- LATE and Alzheimer's Connection: Interestingly, many dementia patients have more than one type, and LATE often co-exists with Alzheimer's. But here's where it gets controversial: LATE can accelerate Alzheimer's progression, making accurate diagnosis crucial.
Understanding LATE Dementia
In LATE, the TDP-43 protein accumulates in the limbic system, impacting memory. Dr. Milano notes, "It mimics Alzheimer's, but it's typically slower and primarily affects memory." Unlike Alzheimer's, LATE usually appears later in life and progresses gradually.
Diagnosing and Treating LATE
New guidelines help doctors identify LATE by observing memory recall challenges and language difficulties. The hippocampus, crucial for memory, shows changes in LATE patients, visible on brain scans.
While there are no treatments yet, research is underway. The South Carolina Alzheimer's Network (SCAN) is a hub for studying various memory disorders, including LATE. Dr. Milano emphasizes the shift in dementia treatment, focusing on the brain's underlying pathology rather than just symptoms. For instance, Leqembi, an Alzheimer's medication, targets amyloid plaques.
And this is the part most people miss: LATE requires a different approach. Researchers at the University of Kentucky are testing the heart drug nicorandil to protect brain tissue and halt hippocampal shrinkage in mild memory loss cases.
The LATE-Alzheimer's Connection
A surprising fact: Many dementia patients have multiple types. When LATE and Alzheimer's coexist, LATE can exacerbate Alzheimer's symptoms. This highlights the importance of precise diagnosis. Dr. Milano stresses, "Not all memory issues are Alzheimer's. LATE is one of many causes." Accurate evaluation is vital for treatment and future planning.
What's your take on this complex dementia landscape? Do you think the focus on underlying pathology will revolutionize dementia treatment? Share your thoughts below!
